The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

We are poised for the market with a clinical pipeline that includes three novel products in late-stage development: Albuferon®, which has completed Phase 3 trials for hepatitis C; BENLYSTA™ (formerly LymphoStat-B®) in Phase 3 trials for systemic lupus; and ABthrax™ in late-stage development for inhalation anthrax.

Both Albuferon and BENLYSTA have the therapeutic potential to change and save lives and the commercial potential to become blockbusters in the marketplace. Each is being co-developed and commercialized in collaboration with a world leader in the pharmaceutical industry – Novartis for Albuferon and GlaxoSmithKline (GSK) for BENLYSTA.

ABthrax is being developed under a contract with the U.S. Government and represents a new way to address the threat of inhalation anthrax. In January 2009, we began delivery of 20,000 doses of ABthrax to the U.S. Strategic National Stockpile for use in the event of an emergency for the treatment of inhalation anthrax.

Right behind these three late-stage products is a high-potential mid-stage pipeline led by our TRAIL receptor antibodies for cancer. We also have substantial financial rights to a number of products in the GSK pipeline. GSK has initiated a Phase 3 trial of darapladib in men and women with chronic coronary heart disease, and has initiated a Phase 3 trial of Syncria® (albiglutide) in type 2 diabetes.

Our manufacturing capability represents a significant strategic advantage. HGS is able to produce and purify multiple protein and antibody drugs in two state-of-the-art process development and manufacturing facilities – totaling approximately 400,000 square feet and offering both small-scale and large-scale production.

Unlike many pre-commercial biopharmaceutical companies, HGS has built a strong cash position that allows us to focus on advancing our lead products toward commercialization as rapidly as possible, while at the same time investing in our early- and mid-stage pipeline. We are committed to achieving and sustaining growth well into the future.